Institutional shares held 60.5 Million
424K calls
190K puts
Total value of holdings $6.48B
$45.3M calls
$20.3M puts
Market Cap $6.71B
62,680,700 Shares Out.
Institutional ownership 96.51%
# of Institutions 601


Latest Institutional Activity in JAZZ

Top Purchases

Q1 2025
Nuveen, LLC Shares Held: 502K ($53.8M)
Q1 2025
Holocene Advisors, LP Shares Held: 492K ($52.7M)
Q1 2025
Bank Of America Corp Shares Held: 994K ($106M)
Q1 2025
Fuller & Thaler Asset Management, Inc. Shares Held: 1.33M ($142M)
Q1 2025
Perpetual LTD Shares Held: 952K ($102M)

Top Sells

Q1 2025
Pacer Advisors, Inc. Shares Held: 845K ($90.4M)
Q1 2025
Millennium Management LLC Shares Held: 21.4K ($2.3M)
Q1 2025
D. E. Shaw & Co., Inc. Shares Held: 66.2K ($7.09M)
Q1 2025
Polaris Capital Management, LLC Shares Held: 879K ($94.1M)
Q1 2025
Avidity Partners Management LP Shares Held: 80K ($8.56M)

About JAZZ

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.


Insider Transactions at JAZZ

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
373K Shares
From 21 Insiders
Grant, award, or other acquisition 266K shares
Open market or private purchase 102K shares
Exercise of conversion of derivative security 4.81K shares
Sell / Disposition
118K Shares
From 25 Insiders
Payment of exercise price or tax liability 33.2K shares
Sale (or disposition) back to the issuer 43.2K shares
Open market or private sale 41.7K shares

Track Institutional and Insider Activities on JAZZ

Follow Jazz Pharmaceuticals plc and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells JAZZ shares.

Notify only if

Insider Trading

Get notified when an Jazz Pharmaceuticals PLC insider buys or sells JAZZ shares.

Notify only if

News

Receive news related to Jazz Pharmaceuticals plc

Track Activities on JAZZ